Systemic Mastocytosis Treatment with Midostaurin: [18 F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome

Burgard C, Rosar F, Khreish F, Ezziddin S (2022)

Publication Type: Journal article

Publication year: 2022

Journal

Diagnostics MDPI

Book Volume: 12

Article Number: 680

Journal Issue: 3

DOI: 10.3390/diagnostics12030680

Abstract

We report the case of a 68-year-old patient with diagnosed systemic mastocytosis and histopathologically confirmed manifestations in the stomach and intestinal tract who underwent18 F-Fluorodeoxyglucose ([18 F]FDG) positron-emission tomography/computed tomography (PET/CT) pre-and post-6-month therapy with midostaurin, an established tyrosine kinase inhibitor. Post-therapeutic [18 F]FDG PET/CT showed decreased multifocal tracer uptake in the known lesions in the gastrointestinal tract, which was consistent with relief of the patient’s symptoms and decrease in serum tryptase level. [18 F]FDG PET/CT may thus be considered a potential method for monitoring the outcome of midostaurin therapy in systemic mastocytosis.

Involved external institutions

Universitätsklinikum des Saarlandes (UKS) DE Germany (DE)

How to cite

APA:

Burgard, C., Rosar, F., Khreish, F., & Ezziddin, S. (2022). Systemic Mastocytosis Treatment with Midostaurin: [18 F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome. Diagnostics, 12(3). https://doi.org/10.3390/diagnostics12030680

MLA:

Burgard, Caroline, et al. "Systemic Mastocytosis Treatment with Midostaurin: [18 F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome." Diagnostics 12.3 (2022).

BibTeX: Download